Login

Join for Free!
118888 members
table of contents table of contents

This work lays the foundation for developing a single Ad vector encoding …


Biology Articles » Immunobiology » An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes » References

References
- An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

  1. Gibbons RV, Vaughn DW: Dengue: an escalating problem.

    Brit Med J 2002, 324:1563-1566. 

  2. Gubler DJ: Dengue and dengue haemorrhagic fever.

    Clin Microbiol Rev 1998, 11:480-496. 

  3. Guzmán MG, Kouri G: Dengue: an update.

    Lancet Infect Dis 2002, 2:33-42.

  4. Rothman AL: Dengue: defining protective versus pathologic immunity.

    J Clin Invest 2004, 113:946-951.

  5. Stephenson JR: Understanding dengue pathogenesis: implications for vaccine design.

    Bull WHO 2005, 83:308-314. 

  6. Innis BL: Antibody responses to dengue virus infection. In Dengue and Dengue Hemorrhagic Fever. Edited by: Gubler DJ, Kuno G. Wallingford, UK: CAB International; 1997:221-243.

  7. Kurane I, Ennis FA: Immunopathogenesis of dengue virus infections. In Dengue and Dengue Hemorrhagic Fever. Edited by: Gubler DJ, Kuno G. Wallingford, UK: CAB International; 1997:273-290.

  8. Mongkolsapaya JW, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G: Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.

    Nat Med 2003, 9:921-927.

  9. Halstead SB, Deen J: The future of dengue vaccines.

    Lancet 2002, 360:1243-1245. 

  10. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A, Kieny MP: Meeting report "Review on flavivirus vaccine development: proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health", 26–27 April Bangkok, Thailand.

    Vaccine 2005, 23:2689-2695. 

  11. Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C, Diehl L, Lyons R, Porter K, Punnonen J: Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.

    Vaccine 2006, 24:335-344. 

  12. Konishi E, Kosugi S, Imoto J: Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice.

    Vaccine 2006, 24:2200-2207.

  13. Mota J, Acosta M, Argotte R, Figueroa R, Méndez A, Ramos C: Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.

    Vaccine 2005, 23:3469-3476.

  14. Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, Porter K: A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

    Virology 2006, 353:166-173.

  15. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R: Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.

    J Virol 2006, 80:9577-9585. 

  16. Hermida L, Bernardo L, Martín J, Alvarez M, Prado I, López C, de la Sierra BC, Martínez R, Rodríguez R, Zulueta A, Pérez AB, Lazo L, Rosario D, Guillén G, Guzmán M: A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates.

    Vaccine 2006, 24:3165-3171. 

  17. Bhamarapravati N, Sutee Y: Live attenuated tetravalent dengue vaccine.

    Vaccine 2000, 18:44-47.

  18. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

    Vaccine 2001, 19:3179-3188.

  19. Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr: Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

    Am J Trop Med Hyg 2003, 69(Suppl 6):17-23.

  20. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W: Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

    Am J Trop Med Hyg 2003, 69(Suppl 6):48-60.

  21. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

    Am J Trop Med Hyg 2002, 66:264-272. 

  22. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Laurent C, Saluzzo JF, Bhamarapravati N: Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.

    Pediatr Infect Disease J 2004, 23:99-109.

  23. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF: Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.

    Vaccine 2006, 24:1238-1241. 

  24. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP: Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in non-human primates.

    J Virol 2000, 74:5477-5485.

  25. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP: Construction, safety, and immunogenicity in nonhuman primates of a yellow fever-dengue virus tetravalent vaccine.

    J Virol 2001, 75:7290-7304.

  26. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP: Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

    Virology 2002, 298:146-159.

  27. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T: Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

    J Virol 2004, 78:4761-4775.

  28. IVR/WHO document, April 2005: New vaccines against infectious diseases: research and development status, updated February 2006 [http://www.who.int/entity/vaccine_research/documents/en/Status_Table.pdf] 

  29. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS: Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

    Am J Trop Med Hyg 2004, 71:811-821.

  30. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS: Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys.

    J Virol 2005, 79:5516-5528. 

  31. Swaminathan S, Khanna N: Viral vaccines for dengue: the present and the future. [http://www.searo.who.int/LinkFiles/Dengue_Bulletin_Volume_27_ch25.pdf]

    WHO Den Bull 2003, 27:181-191.

  32. Pugachev KV, Guirakhoo F, Trent DW, Monath TP: Traditional and novel approaches to flavivirus vaccines.

    Intl J Parasitol 2003, 33:567-582.

  33. Zhou H, Deem MW: Sculpting the immunological response to dengue fever by polytopic vaccination.

    Vaccine 2006, 24:2451-2459.

  34. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM: Dengue virus infectivity depends on envelope protein binding to target cell heparin sulfate.

    Nat Med 1997, 3:866-871.

  35. Mégret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger J, Wright PJ, Young P, van Regenmortel MHV, Deubel V: Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein.

    Virology 1992, 187:480-491. 

  36. Roehrig JT, Bolin RA, Kelly RG: Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.

    Virology 1998, 246:317-328. 

  37. Crill WD, Roehrig RT: Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

    J Virol 2001, 75:7769-7773.

  38. Simmons M, Nelson WM, Wu SJL, Hayes CG: Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

    Am J Trop Med Hyg 1998, 58:655-662.

  39. Simmons M, Murphy GS, Hayes CG: Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

    Am J Trop Med Hyg 2001, 65:159-161.

  40. Hung JJ, Hsieh MT, Young MJ, Kao CL, King CC, Chang W: An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells.

    J Virol 2004, 78:378-388. 

  41. Jaiswal S, Khanna N, Swaminathan S: High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.

    Protein Exp Purif 2004, 33:80-91.

  42. Khanam S, Khanna N, Swaminathan S: Induction of antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.

    Vaccine 2006, 24:6513-6525. 

  43. Khanam S, Etemad B, Khanna N, Swaminathan S: Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.

    Am J Trop Med Hyg 2006, 74:266-277.

  44. Trirawatanapong T, Chandran B, Putnak R, Padmanabhan R: Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody.

    Gene 1992, 116:139-150. 

  45. Jaiswal S, Khanna N, Swaminathan S: Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2.

    J Virol 2003, 77:12907-12913. 

  46. Shiver JW, Emini EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

    Annu Rev Med 2004, 55:355-372. 

  47. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ: Development of a preventive vaccine for Ebola virus infection in primates.

    Nature 2000, 408:605-609.

  48. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ: Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue virus type 2 challenge.

    Vaccine 2000, 18:3113-3122.

  49. Delenda C, Staropoli I, Frenkiel MP, Cabanié L, Deubel V: Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice.

    J Gen Virol 1994, 75:1569-1578. 

  50. Putnak RP, Feighny R, Burrous J, Cochran M, Hackett C, Smith G, Hoke C: Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge.

    Am J Trop Med Hyg 1991, 45:159-167.

  51. He TC, Zhou S, DaCosta LT, Yu J, Kinzler KW, Vogelstein B: A simplified system for generating recombinant adenoviruses.

    Proc Natl Acad Sci USA 1998, 95:2509-2514.


rating: 0.00 from 0 votes | updated on: 20 Jul 2009 | views: 6364 |

Rate article:







excellent!bad…